4 Topic Commentaries

Amyloid Seeds Emerge as Blood Biomarker

Amyloid Seeds Emerge as Blood Biomarker

• 

  Valerie Daggett, PhD

  Bioengineering; protein misfolding diagnostics

  •

  University of Washington

  What we show here is that SOBA may be the basis of such a test.

  Source
• 

  Suélyn Koerich, PhD

  Neurology; Alzheimer’s disease research

  •

  McGovern Medical School, UTHealth Houston

  However, recent studies have shown that biologically active amyloid beta oligomeric seeds might be present in blood of Alzheimer’s disease patients and preclinical models, suggesting that this biological fluid may play an important role in the spreading of the disease.

  Source
• 

  Abhay R. Moghekar, MBBS

  Neurology; neurodegenerative biomarkers

  •

  Johns Hopkins University School of Medicine

  My guess is that in 50% to 75% of the patients, the blood test will provide an answer as to whether or not they have Alzheimer’s.

  Source
• 

  Hyun-Sik Yang, MD

  Neurology; Alzheimer’s disease biomarkers

  •

  Harvard Medical School; Brigham and Women’s Hospital

  But now we are seeing that pTau217 can be detected years earlier, well before clear abnormalities appear on amyloid PET scans.

  Source